Adaptive Biotechnologies Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ADPT Nasdaq 8731 https://www.adaptivebiotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adaptive Biotechnologies Corp

Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth - Jan 30th, 2023 12:21 pm
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023 - Jan 23rd, 2023 9:05 pm
Capella Space Raises $60M in Growth Equity from the United States Innovative Technology Fund to Expand Satellite Imaging Capacity and Meet Rapidly Growing Customer Demand - Jan 10th, 2023 2:00 pm
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference - Dec 27th, 2022 9:05 pm
Adaptive Biotechnologies (NASDAQ:ADPT shareholders incur further losses as stock declines 17% this week, taking three-year losses to 76% - Dec 20th, 2022 11:14 am
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting - Dec 10th, 2022 3:00 pm
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting - Dec 5th, 2022 12:30 pm
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA) - Dec 1st, 2022 12:30 pm
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference - Nov 21st, 2022 9:05 pm
New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results - Nov 21st, 2022 12:30 pm
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Lags Revenue Estimates - Nov 3rd, 2022 10:35 pm
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results - Nov 3rd, 2022 8:05 pm
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers - Oct 11th, 2022 12:05 pm
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022 - Oct 5th, 2022 8:05 pm
Institutional owners may consider drastic measures as Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) recent US$104m drop adds to long-term losses - Sep 15th, 2022 10:48 am
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million - Sep 12th, 2022 12:30 pm
Adaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference - Sep 2nd, 2022 12:00 pm
3 Cathie Wood Stocks for the Future - Aug 14th, 2022 3:13 pm
Adaptive Biotechnologies Corporation (ADPT) Q2 2022 Earnings Call Transcript - Aug 4th, 2022 4:00 am
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates - Aug 3rd, 2022 9:35 pm